{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-25-000028","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.311680+00:00","generated_at":"2026-05-26T01:14:55.217383+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xencor Q4 net loss widens to $45.6M; full-year revenue falls 37% to $110.5M","bullets":["Q4 revenue $52.8M (+3.5% YoY) driven by milestone payments; full-year revenue $110.5M vs $174.6M.","FY 2024 net loss $232.6M ($3.58 diluted EPS) vs $133.1M ($2.20); R&D spend dropped to $227.7M.","Cash $706.7M at Dec 31; 2025 guidance $535-585M, runway into 2028.","Pipeline: XmAb942 healthy-volunteer data 1H 2025; XmAb819 ccRCC data 2H 2025; plamotamab RA Ph1b/2a start 1H 2025.","Vudalimab development paused; milestone revenue of $30M (Amgen) and $4M (Novartis) received in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-25-000028","json":"https://secwatch.observer/filing/0001326732-25-000028.json","markdown":"https://secwatch.observer/filing/0001326732-25-000028.md","text":"https://secwatch.observer/filing/0001326732-25-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673225000028/0001326732-25-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673225000028/xncr-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:14:55.217383+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}